Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 3,401–3,500 of 4,628
Current and Future Therapies for Idiopathic Pulmonary Fibrosis
Spagnolo, P., Bonella, F., Vašáková, M., Kreuter, M., & Maher, T. M. (2015) · Pulmonary Therapy · doi:10.1007/s41030-015-0009-4 · Cited by 2
Khor, Y. H., Ng, Y., Goh, N. S. L., McDonald, C. F., & Holland, A. E. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012647 · Cited by 2
Emerging and potential treatment options for sarcoidosis
Bandyopadhyay, D., & Judson, M. A. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1411260 · Cited by 2
New Diagnostic Guidelines for Idiopathic Pulmonary Fibrosis
Kwon, B. S., & Song, J. W. (2019) · Korean Journal of Medicine · doi:10.3904/kjm.2019.94.2.173 · Cited by 2
Interstitial lung disease: perhaps unclassifiable, but not untreatable
Oldham, J. M. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30343-1 · Cited by 2
Facing the Challenge of Post COVID-19 Pulmonary fibrosis: What is so unique about it?
Ghose, M., & Islam, T. (2020) · Bangladesh Critical Care Journal · doi:10.3329/bccj.v8i2.50028 · Cited by 2
Macisaac, S., & Kolb, M. R. J. (2021) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2021.1899775 · Cited by 2
Self-citationThe impact of SARS-COV2 pandemic on the management oF IPF patients: Our narrative experience
Benfante, A., Messina, R., Piccionello, I., Liberti, R., Principe, S., & Scichilone, N. (2021) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2021.102038 · Cited by 2
Johannson, K. A., Collard, H. R., & Richeldi, L. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.014 · Cited by 2
Self-citationKunadu, A. Q., Alqalyoobi, S., Frere, R. C., & Obi, O. N. (2021) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2021.101472 · Cited by 2
Akute Exazerbation der idiopathischen Lungenfibrose
Polke, M., Kahn, N. C., & Kreuter, M. (2021) · Pneumologie · doi:10.1055/a-1273-4105 · Cited by 2
“[28] Richeldi L, du Bois RM, Raghu G et al.”
BackgroundTomassetti, S., Sebastiani, A., Caminati, A., Oggionni, T., Davì, M., Ghirardini, A., & Martinoli, M. M. (2021) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v38i3.11400 · Cited by 3
Kostorz‐Nosal, S., Jastrzębski, D., Kubicki, P., Galle, D., Gałeczka‐Turkiewicz, A., Toczyłowska, B., & Ziora, D. I. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133657 · Cited by 2
Discovery and Development of Nintedanib: A Novel Antiangiogenic and Antifibrotic Agent
Roth, G. J., Binder, R., Colbatzky, F., Dallinger, C., Schlenker‐Herceg, R., Hilberg, F., Wollin, L., Park, J., Pautsch, A., & Kaiser, R. (2016) · Wiley eBooks · doi:10.1002/9783527800315.ch11 · Cited by 2
Self-citationIs nintedanib effective for idiopathic pulmonary fibrosis?
Jeldres, A., & Gonzalo Labarca, T. (2017) · Medwave · doi:10.5867/medwave.2017.6918 · Cited by 2
Home spirometry for idiopathic pulmonary fibrosis: ready for prime time?
Maher, T. M. (2017) · European Respiratory Journal · doi:10.1183/13993003.01403-2017 · Cited by 2
Connective-Tissue Disease-Associated Interstitial Lung Disease
Nunès, H., Uzunhan, Y., Valeyre, D., et al. (2016) · CRC Press eBooks · doi:10.3109/9781420053449-21 · Cited by 2
Shi, L. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc271 · Cited by 2
Pulmonary and Critical Care Medicine
Kruse, D. A., & Bailey, K. L. (2021) · Springer eBooks · doi:10.1007/978-3-030-76271-1_25 · Cited by 2
Editorial: Interstitial Lung Disease Around the World
Wijsenbeek, M. S., Lee, J. S., Udwadia, Z. F., & Kreuter, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.865334 · Cited by 2
Stylianou, P., Rushwan, S., Wang, W., Miah, M. A., Darweesh, O., MacKinnon, A. C., Roach, K. M., Hitchman, C. J., Gonchar, O., Thorpe, S. D., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.12.503154 · Cited by 2
Leavy, O. C., Kawano-Dourado, L. B., Stewart, I. D., et al. (2022) · medRxiv · doi:10.1101/2022.09.27.22280286 · Cited by 2
Characterization of Pro-Fibrotic Signaling Pathways using Human Hepatic OrganoidsPreprint
Guan, Y., Fang, Z., Hu, A., Roberts, S., Wang, M., Ren, W., Johansson, P. K., Heilshorn, S. C., Enejder, A. M. K., & Peltz, G. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.25.538102 · Cited by 2
Noradrenergic input from sympathetic nerves to fibroblasts regulates lung fibrosis
Ishikawa, G., Ghincea, A., Peng, X., Shao, S., McGovern, J., Zielonka, J., Jeevanandam, A., Woo, S., Okuno, D., Yu, S., et al. (2026) · Science Translational Medicine · doi:10.1101/2024.09.09.611003 · Cited by 3
Rare Variants and Survival of Patients with Idiopathic Pulmonary FibrosisPreprint
Alonso-González, A., Jáspez, D., Lorenzo-Salazar, J. M., Ma, S., Strickland, E., Mychaleckyj, J. C., Kim, J. S., Huang, Y., Adegunsoye, A., Oldham, J. M., et al. (2024) · medRxiv · doi:10.1101/2024.10.12.24315151 · Cited by 2
LAPTM4B Alleviates Pulmonary Fibrosis by Enhancing NEDD4L-Mediated TGF-β Signaling SuppressionPreprint
Xu, K., Pan, X., Lian, H., Wang, Y., Wan, R., Li, Z., Pan, X., Li, Y., Yang, J., Rosas, I. O., et al. (2024) · eLife · doi:10.7554/elife.101412.1 · Cited by 3
Mia, M. M., Selvan, A., Nilanthi, U., & Singh, M. K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.23.661212 · Cited by 5
Rutherford, E. N., Sun, D., Lim, K., Edgar, J. R., Matesic, L. E., Marciniak, S. J., Rawlins, E. L., & Dickens, J. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.22.665497 · Cited by 2
Sisson, T. H., Fortier, S. M., Tsoi, L. C., Alonzo, R., Subbotina, N., Warnock, M., Mann, K. M., Gutor, S. S., Hartman, J. C., Gudjonsson, J. E., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6951289/v1 · Cited by 3
Alber, A. B., Kwong, G., Gupta, V. K., Dooley, P. E., Patel, J., Bawa, P., Minakin, K., Jones, D. L., Gopal, D., Souza, H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.30.702837 · Cited by 4
Fibrotic Signaling in the Lung
Dutta, J. A., Bahudhanapati, H., Tan, J., Goldblum, A., & Kass, D. J. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_4 · Cited by 2
Adjunctive therapies in idiopathic pulmonary fibrosis—where do we stand?
Nokes, B. T., & Afshar, K. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.11.131 · Cited by 2
Raparia, K., & Raj, R. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0134-ra · Cited by 1
Kersten, B. E., & Vonk, M. C. (2019) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-019-00119-9 · Cited by 2
Fahim, A. (2021) · The Clinical Respiratory Journal · doi:10.1111/crj.13322 · Cited by 1
Vancheri, C., Bengus, M., Bianchino, L., et al. (2021) · Pulmonary Therapy · doi:10.1007/s41030-021-00155-8 · Cited by 1
Miguel, T. P., POLO, V. O., Lizán, L., et al. (2022) · Open Respiratory Archives · doi:10.1016/j.opresp.2022.100158 · Cited by 1
Therapie der Lungenfibrosen: Interdisziplinäre Diagnostik bessert Therapiechancen
Prasse, A. (2022) · Deutsches Ärzteblatt · doi:10.3238/perspneumo.2022.04.29.01 · Cited by 1
Better to Be an Agnostic than a Believer (at Least in Pulmonary Fibrosis)
Sgalla, G., & Richeldi, L. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202207-1437ed · Cited by 1
Self-citationCalle, C. A., Rosales, M. F., & Eddyn, R. M. (2023) · Revista americana de medicina respiratoria · doi:10.56538/ramr.vfnq2915 · Cited by 1
Pharmacological management of systemic sclerosis associated interstitial lung disease
Dixon, G., Adamali, I., Adamali, H. I., Barratt, S. L., Gunarwardena, H., & Pauling, J. D. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2198640 · Cited by 2
Khan, M. A., Ghamdi, B. A., Alhamadi, M., Rajendram, R., Alyami, S., Al-Gamedi, M., Al-Harbi, A., & Al-Jahdali, H. H. (2023) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_264_22 · Cited by 3
Bleinc, A., Blin, T., Legué, S., Mankikian, J., Plantier, L., & Marchand-Adam, S. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2023.03.004 · Cited by 2
Oral Health and Wellbeing of Patients with Idiopathic Pulmonary Fibrosis
Barczyk, A., Białas, A. J., Piotrowski, W. J., Klosek, S. K., & Majewski, S. (2023) · Journal of Health Study and Medicine · doi:10.2478/jhsm-2023-0001 · Cited by 1
A Test to Comprehensively Capture the Known Genetic Component of Familial Pulmonary Fibrosis
Villeneuve, J., Tremblay, É., Gaudreault, N., Armero, V. E. S., Boudreau, D. K., Li, Z., Renaut, S., Dion, G., & Bossé, Y. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0009ma · Cited by 2
Mullor, M. M. G., Arenas-Jiménez, J. J., Vacas, A. U., García‐Manso, I. G., Pérez, J. L. P., Serra, N. S., & Sevila, R. G. (2024) · Radiología (English Edition) · doi:10.1016/j.rxeng.2023.03.006 · Cited by 1
Aburto, M., Rodríguez-Portal, J. A., Fernández‐Fabrellas, E., Sevila, R. G., Lara, S. H., de Miguel, E. B., Ruiz, J. M. G., Molina‐Molina, M., Safont, B., Mayoral, R. G., et al. (2024) · Open Respiratory Archives · doi:10.1016/j.opresp.2024.100334 · Cited by 1
Repositioning compounds for idiopathic pulmonary fibrosis treatment: seeking the future in the past
Crestani, B. (2024) · European Respiratory Journal · doi:10.1183/13993003.00678-2024 · Cited by 1
Decoding Molecular Heterogeneity in Idiopathic Pulmonary Fibrosis
Matson, S. M. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202406-1208ed · Cited by 1
Variable Duration Trial as an Alternative Design for Continuous Endpoints
Ganju, J., & Guoguang, J. (2024) · Pharmaceutical Statistics · doi:10.1002/pst.2418 · Cited by 1
Chang, Y., Tsai, M., Chang, Y.-P., Liao, C.-C., Lin, Y.-T., Lai, C., Lin, M., & Huang, K.-T. (2024) · Drugs - Real World Outcomes · doi:10.1007/s40801-024-00443-0 · Cited by 2
Kang, J., Lee, K. H., Lee, J. H., Jeong, Y. Y., Choi, S. M., Kim, H. C., Park, J. H., Lee, H.-K., Yong, S. J., Choi, H. S., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1451447 · Cited by 3
Inada, S., Nakashima, T., Masuda, T., Shimoji, K., Sakamoto, S., Yamaguchi, K., Horimasu, Y., Iwamoto, H., Fujitaka, K., Hamada, H., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03933-8 · Cited by 2
Current approaches for the treatment of chronic respiratory disorders and limitations
Yeung, S., Loo, C., Saeid, A. B., & Lee, W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-27345-2.00002-3 · Cited by 4
Araldi, G. L., Hwang, Y., & Raghu, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111827 · Cited by 2
Self-citationPrevalence, Clinical Features, and Outcomes of Young Patients with Idiopathic Pulmonary Fibrosis
Lee, J., Kim, K., Nam, J. H., Choi, J. Y., Rhee, C. K., & Jo, Y. S. (2024) · Respiration · doi:10.1159/000541692 · Cited by 3
Krzykawski, K., Maciejczyk, T., Mól, P., Sadowski, J., Zabawa, B., Dołęga, J., Papież, Ł. S., Hudzińska, P., Sieńko, A., & Łabuś, M. (2024) · Quality in Sport · doi:10.12775/qs.2024.36.56515 · Cited by 1
Neutral LPAR1 Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis
Wang, X. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00263 · Cited by 1
Santibañez, V. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.02.004 · Cited by 1
Aliaga, F. A., & Vial, M. R. (2025) · Current Pulmonology Reports · doi:10.1007/s13665-025-00372-5 · Cited by 1
Cost-effectiveness of novel diagnostic tools for idiopathic pulmonary fibrosis in the United States
Cadham, C. J., Reicher, J. J., Muelly, M. C., & Hutton, D. W. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-12506-1 · Cited by 2
Predicting Failure: Can Blood Biomarkers Identify Likely Treatment Non‐Responders in IPF ?
Maher, T. M. (2025) · Respirology · doi:10.1111/resp.70041 · Cited by 1
“In clinical trials, both pirfenidone and nintedanib, on average, slow but do not prevent disease progression [2, 3].”
Ma, H., Huang, Z., Jeet, S., Emerson, C., Bender, H. S., Ren, Q., & Ding, N. (2025) · iScience · doi:10.1016/j.isci.2025.112778 · Cited by 2
Targeting the AXL pathway: a promising strategy for pulmonary fibrosis
Larson‐Casey, J. L., & Carter, A. B. (2025) · European Respiratory Journal · doi:10.1183/13993003.00114-2025 · Cited by 1
Breaking new ground in pulmonary fibrosis: Targeting Pathways and Therapeutic Innovations
Mishra, S. (2025) · The Journal of Association of Chest Physicians · doi:10.4103/jacp.jacp_1_25 · Cited by 1
Prospects of pirfenidone use in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
Трушенко, Н. В., Levina, I. A., Lavginova, B. B., Suvorova, O., & Avdeev, S. N. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-201 · Cited by 2
Prognosis and prognostic factors for chronic fibrosing idiopathic interstitial pneumonias
Nishikiori, H., & Chiba, H. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.06.005 · Cited by 2
Hur, J., Rhee, C. K., Choi, J. Y., & Jo, Y. S. (2025) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2025.102376 · Cited by 6
Iwata, K., Yamazaki, K., Kushima, R., et al. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5369-25 · Cited by 1
Badia, M. B., Iglesias, D., Persentili, S. E., Jiménez, M., Rivera‐Ortega, P., & Bordas-Martínez, J. (2025) · Medicina · doi:10.3390/medicina61081385 · Cited by 2
“Telemonitoring systems involving smartphone applications, home spirometry, or wearable devices have shown promising outcomes in ILD management [7–9].”
Stratifying GAP Stages by MUC5B rs35705950 T-Allele Carriage Refines Survival Prediction in IPF
van der Vis, J. J., Prasse, A., Renzoni, E. A., Stock, C. J. W., Maher, T. M., Bonella, F., Borie, R., Crestani, B., Wuyts, W. A., Molyneaux, P. L., et al. (2025) · Lung · doi:10.1007/s00408-025-00837-z · Cited by 2
Zheng, J., zhou, N., & Pang, D. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1561440 · Cited by 1
Discovery of novel anti-fibrotics through phenotypic screening
Lapthorn, A. R., Harding, S. L., Feltham, K. M., Ilg, M. M., & Cellek, S. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104450 · Cited by 1
Regional Medical Collaboration May Lead to Early Detection of Interstitial Lung Disease
Zaizen, Y., Tominaga, M., Matama, G., Ichikawa, Y., Gohara, R., Hiyama, J., Ide, S., Kamimura, T., Kinoshita, M., Kitasato, Y., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14175923 · Cited by 1
“The antifibrotic agents pirfenidone and nintedanib have been shown to reduce the decline in forced vital capacity (FVC) in patients with IPF [4,5].”
Tagami, Y., Kawai, M., Okamura, K., & Kitamura, H. (2025) · Journal of Clinical Question · doi:10.69854/jcq.2025.0021 · Cited by 1
Sadek, M. A., ElBishbishy, R. M., Lotfy, R. M., Fayez, N., Sayed, G. A., El‐Shiekh, R. A., & Hal, D. M. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202500981 · Cited by 3
“Although pirfenidone and nintedanib are the primary approved antifibrotic drugs for treating PF, they cannot halt disease progression or reverse the decline in lung function [217, 218, 223].”
Genetic Familial Interstitial Lung Disease
Fernandez, R. J., & Kropski, J. A. (2025) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2025.07.008 · Cited by 1
Optimized Synthetic Flavonols Support Senescence Clearance and Lung Fibrosis Resolution
Meridew, J. A., Vu, J. A., Chow, D., Espinosa, A. M. D., Saraf, N., Gao, A. Y., Espíndola‐Netto, J. M., Dresler, S. R., Whaley, M. G., Choi, K. M., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00231 · Cited by 2
Impact of medications on lung function in fibrotic hypersensitivity pneumonitis
Abe, T., Okamoto, T., Shimamura, T., Ejima, M., Sonoda, S., Shirai, T., Ishizuka, M., Furusawa, H., Tateishi, T., Hanazawa, R., et al. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.09.001 · Cited by 2
Namas, R. A., Qassimi, S. A., Elarabi, M., Khan, S., Almarzooqi, A. M., Mubashir, A., Hafiz, W. A., & Chapman, J. (2025) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000002281 · Cited by 2
Ali, H. A., Metwally, S. A., Sayed, M. H. E., & Zakaria, S. H. (2025) · Pediatric Pulmonology · doi:10.1002/ppul.71299 · Cited by 1
“…in the role of VEGF in the pathogenesis of ILD, with the development of nintedanib for the treatment of interstitial pulmonary fibrosis (IPF), a novel triple tyrosine kinase inhibitor of VEGF, fibroblast ‐ derived growth factor (FGF), and platelet ‐ derived growth factor (PDGF) receptors [11].”
Interstitial Lung Disease in 2025—Progress, Challenges, and Hope Ahead
Sehgal, S., & Mehta, A. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186673 · Cited by 1
“Therapeutically, the last transformative breakthrough in ILD came in 2014 with the introduction of antifibrotic agents, which slowed IPF disease progression for the first time and later demonstrated benefits across a broader spectrum of progressive fibrosing ILD [3,4].”
Kass-Gergi, S., Holcomb, N. P., Maiden, M. M., Eisenlohr, L. C., & Vaughan, A. E. (2025) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00189.2025 · Cited by 2
Thivent, S., Neder, J. A., Bernard, A., Coudurier, M., Guinot, M., Hérengt, F., Vergès, S., & Marillier, M. (2025) · Experimental Physiology · doi:10.1113/ep091542 · Cited by 1
Wu, Y., & Ou, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00048-2 · Cited by 1
Evaluation of TAM Receptor Targeting in Pathophysiology of Idiopathic Pulmonary Fibrosis
Vercellino, N., Ferreira, L. L., Zoppis, E., Tizio, A. D., Ahvaz, Z. S., Minisini, R., Gavelli, F., Sainaghi, P. P., Patrucco, F., & Bellan, M. (2025) · Medicina · doi:10.3390/medicina61101837 · Cited by 2
“In two consecutive trials (INPULSIS-1 and INPULSIS-2), a total of 1066 patients with IPF were randomly assigned to receive Nintedanib 150 mg or placebo twice daily for 52 weeks [17].”
Lee, J. H., Park, S., & Yoon, H. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251390672 · Cited by 2
Borghetti, P., D’Angelillo, R. M., Facheris, G., Borghesi, A., Bruni, A., Ceruti, P., Ferrari, K., Filippi, A. R., Ramella, S., Signorelli, D., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108807 · Cited by 2
Innovative strategies for anti-fibrotic drugs discovery from traditional Chinese medicine
Xin, G., Wang, L., Zhou, Q., Zhang, S., Wei, Z., Li, L., Chen, W., Sun, D., Chen, S., Cong, Z., et al. (2025) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2025.10.005 · Cited by 3
Renner, A., Vertanen, E., Sutinen, E., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-097246 · Cited by 1
Acetylshikonin alleviates pulmonary fibrosis through inhibition of the STAT3 signaling pathway
Qiu, M., Cheng, J., Sun, A., Zhou, Y., Ma, C., Ye, Y., Zhou, X. Y., Xu, Y., Hong, X., Zhao, C., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115811 · Cited by 1
Yüksel, A., Nezalzova, P., & Ulubay, G. (2025) · Archives of Medical Science · doi:10.5114/aoms/210329 · Cited by 1
Barton, C., Hoffman, M., Cox, N. S., Glenn, L. M., Lee, J. Y. T., Cox, I. A., Goh, N. S. L., Troy, L. K., Mackintosh, J. A., Chambers, D. C., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03442-z · Cited by 1
Imai, R., Bermea, R. S., Zhao, S. H., Singh, A., Synn, A. J., Flashner, B. M., Munchel, J. K., Rice, M. B., Shea, B. S., & Hallowell, R. W. (2025) · European Respiratory Journal · doi:10.1183/13993003.01638-2025 · Cited by 4
Nishikiori, H., Yama, N., Hirota, K., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-04062-5 · Cited by 1
Progressive pulmonary fibrosis
Bajwa, R. U. D., Lancaster, D., Desai, S. R., & George, P. M. (2025) · European Radiology · doi:10.1007/s00330-025-12212-w · Cited by 1
Kishaba, T., Higa, M., & Nagano, H. (2025) · Cureus · doi:10.7759/cureus.99813 · Cited by 2
“The ASCEND and INPULSIS trials demonstrated that antifibrotic therapies reduce the rate of FVC decline and delay time to acute exacerbation or death [2,26].”
Singh, P., Patel, P. K., Kasam, R. K., Lawson, R., Ediga, H. H., Jegga, A. G., & Madala, S. K. (2026) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00204.2025 · Cited by 1
Young, O. N., Widdop, R. E., & Bourke, J. E. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2616755 · Cited by 1
Fares, W. H., & Castagna, M. (2026) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1177/19412711251414386 · Cited by 1
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.